Pax-3 Antibody (6288D4a): sc-81351
- Pax-3 Antibody (6288D4a) is a mouse monoclonal IgG1, cited in 3 publications, provided at 100 µg/ml
- raised against a recombinant protein corresponding to a region near the C-terminus of Pax-3 of human origin
- recommended for detection of Pax-3 of mouse, rat and human origin by WB and IP
- See Pax-3/7 (B-5): sc-365843 for Pax-3 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Pax-3 Antibody (6288D4a). This work is in progress.
Pax-3 Antibody (6288D4a) is a mouse monoclonal IgG1 antibody that detects Pax-3 in mouse, rat, and human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Pax-3 is a crucial DNA-binding protein that plays a significant role during early neurogenesis, characterized by a unique structure that includes both a paired domain and a paired-type homeodomain. This structural configuration is essential for regulating gene expression during nervous system development. Pax-3 is expressed in mitotic cells located in the ventricular zone of the developing spinal cord, as well as in distinct regions of the hindbrain, midbrain, and diencephalon. In 10-12 day embryos, Pax-3 expression extends to neural crest cells in the developing spinal ganglia, craniofacial mesectoderm, and limb mesenchyme, highlighting its importance in various developmental processes. Mutations in Pax-3 have been linked to Waardenburg syndrome, a genetic condition that can lead to hearing loss and pigmentation abnormalities, underscoring Pax-3′s critical role in both development and health. Anti-Pax-3 antibody (6288D4a) is an invaluable tool for researchers studying these developmental pathways and their implications in genetic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Pax-3 Antibody (6288D4a) References:
- Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. | Hathaway, JD. and Haque, A. 2011. Open Cancer J. 4: 1-6. PMID: 24790680
- PAX3 and PAX7 as upstream regulators of myogenesis. | Buckingham, M. and Relaix, F. 2015. Semin Cell Dev Biol. 44: 115-25. PMID: 26424495
- The expression and function of PAX3 in development and disease. | Boudjadi, S., et al. 2018. Gene. 666: 145-157. PMID: 29730428
- Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. | Singh, S., et al. 2022. Sci Transl Med. 14: eabq2096. PMID: 35857643
- PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets. | Zhang, S., et al. 2022. Mol Cell. 82: 4428-4442.e7. PMID: 36395771
- Regulation of Pax3 by Proteasomal Degradation of Monoubiquitinated Protein in Skeletal Muscle Progenitors. | Boutet, SC., et al. 2023. Cell. 186: 2035. PMID: 37116471
- Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3-FOXO1 in rhabdomyosarcoma. | Sroka, MW., et al. 2023. Proc Natl Acad Sci U S A. 120: e2303859120. PMID: 37639593
- PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors. | Searcy, MB., et al. 2023. Nat Commun. 14: 7291. PMID: 37968277
- PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution. | Asante, Y., et al. 2023. Nat Commun. 14: 8361. PMID: 38102136
- KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma. | Kim, YY., et al. 2024. Nat Commun. 15: 1703. PMID: 38402212
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pax-3 Antibody (6288D4a) | sc-81351 | 100 µg/ml | $339.00 |